ArticleCureus2024

Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment.

Nabiha Saeed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.